![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 24, 2021 1:15:03 AM
I think the challenge to value NPHC is that the return to big pharma is many billions a year. I think a multiple of 3x to 5 x of the yearly return is reasonable.
MS $15 BILLION YEARLY market. Pain $100 BILLION YEARLY Nerve agent $75 MILLION YEARLY.
So that’s almost a 200 billion yearly industry. And if they even got 10% market share that’s $20 billion yearly return.
Anything is possible right now.
The only reason they have the urgency to get current and restate their IP would be for an acquisition / JV and government contracts.
Once this is completed in the very near future there will be way to contain the quick rise to $0.25 to $0.50
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM